2023-508126-95-00招募中1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours
Karolinska University Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年9月12日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Robert Bränström
Scientific
Karolinska University Hospital
研究点 (1)
Loading locations...
相似试验
招募中
1 期
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
招募中
1 期
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors2022-502867-39-00Amgen Inc.58
招募中
不适用
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid TumorsjRCT2031230002Astrazeneca K.K417
招募中
不适用
A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with advanced solid malignant tumorsmelanomaSolid Tumors10018865NL-OMON53468Kling Biotherapeutics B.V.22
暂停
2 期
ECUR-506 in Neonatal OTC Deficiency Phase I/IIOrnithine Transcarbamylase (OTC) DeficiencyGenetic DiseasesISRCTN10957794Fortrea Development Ltd13